Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SQLE | Q14534 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4432851 | 1.00 | LMNA (0.34) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL14110947 | 0.81 | LMNA (0.33) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3142339 | 0.75 | LMNA (0.34) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL2770183 | 0.75 | LMNA (0.37) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3142336 | 0.75 | LMNA (0.34) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL2770182 | 0.75 | LMNA (0.37) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL9633566 | 0.75 | LMNA (0.34) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL5168918 | 0.71 | LMNA (0.36) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL5168914 | 0.71 | LMNA (0.36) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL5168923 | 0.71 | LMNA (0.33) | LMNAADRA2ACYP2D6SLC6A2SQLE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121572-A2 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | Auspex Pharmaceuticals Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073863-A2 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-4751245-A | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E. R. SQUIBB & SONS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0251574-A2 | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E.R. Squibb & Sons, Inc. (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167312-A1 | PREPARATION AND UTILITY OF SUBSTITUTED ALLYLAMINES | UGT1A7, UGT2B7, UGT1A10 | LMNA 974/4885ADRA2A 29/4885CYP2D6 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.